|
|
 | | | |
- close
- close
- close
- close
Sinovac Biotech (SVA) |
Benzinga
7 hrs ago
Comment
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for...
Benzinga
May 15
Comment
In a research report published Wednesday, Morgan Stanley analyst Bin Li upgraded Sinovac Biotech Ltd. (NASDAQ: SVA) from Underweight to Equal-Weight and raised the price target from $1.40 to $3.40.
In the report, Morgan Stanley noted, "Positive...
Benzinga
May 15
Comment
Sinovac Biotech (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst &...
Benzinga
May 6
Comment
Sinovac (NASDAQ: SVA) has responded to recent reports of deaths from SARS-like virus in Saudi Arabia. Five Saudis were reported on May 2 to have died from the virus.
"Based on the news reports, the new virus was first detected in mid-2012 and...
StreetInsider.com
Apr 18
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Sinovac+Biotech%2C+Ltd+%28SVA%29+Posts+Q4+Loss+of+10cShare/8261783.html for the full story.
Benzinga
Apr 16
Comment
Randgold Resources (NASDAQ: GOLD) soared 5.79% to $73.04 in the pre-market trading. Randgold's PEG ratio is 1.75.
Silver Standard Resources (NASDAQ: SSRI) moved up 4.19% to $7.70 in the pre-market session. SSRI's trailing-twelve-month operating...
Benzinga
Apr 15
Comment
Sprint Nextel (NYSE: S) soared 15.27% to $7.17 in the pre-market trading after Dish Network (NASDAQ: DISH) offered to acquire the company in a $25.5 billion deal.
Sinovac Biotech (NASDAQ: SVA) moved up 8.31% to $4.17 in the pre-market session....
Benzinga
Apr 8
Comment
Lufkin Industries (NASDAQ: LUFK) soared 37.35% to $87.81 in the pre-market trading. GE (NYSE: GE) announced its plans to buy Lufkin Industries for about $3 billion.
BioCryst Pharmaceuticals (NASDAQ: BCRX) moved up 20% to $2.04 in the pre-market...
Benzinga
Mar 15
Comment
Aegis Capital analyst Raghuram Selvaraju published a report on Sinovac Biotech (NASDAQ: SVA) that maintained its Hold rating and raised the price target to $4 per share.
Aegis Capital reported that, “Sinovac Biotech announced preliminary...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
